Notable approval for Stealths elamipretide On September 19, 2025, the FDA granted accelerated approval to elamipretide (now marketed as Forzinity) for Barth syndrome, awarding a Rare Disease Priority Review Voucher
Among those who used a GLP-1 or GLP-1/GIP medication exclusively for weight loss, those numbers were 91.4% [85.697.2%], 80.2% [71.988.6%], 21.4% [12.430.3%], and 0.9% [0.02.6%], respectively
Inflammation Control Without NSAIDs
Discover Olivella: Premium Ultra Refined Olive Oil Skincare At Olivella , we specialize in olive oil-based skincare products designed to nourish, protect, and enhance your natural beauty
For semaglutide, many studies have been conducted to test its effectiveness and safety
The manufacturer, Novo Nordisk, reported that patients taking the medication did not experience a slower decline in memory or thinking skills compared to those taking a placebo